Coherus Oncology, Inc. 8-K

What Happened
Coherus Oncology, Inc. announced on June 12, 2026 that its Audit Committee dismissed Ernst & Young LLP (EY) as the company’s independent registered public accounting firm, effective that date, and selected PricewaterhouseCoopers LLP (PwC) to serve as the new independent auditor for the fiscal year ending December 31, 2026 (subject to standard client acceptance procedures). EY’s audit reports on the consolidated financial statements for the years ended December 31, 2025 and 2024 were unqualified and contained no disclaimers. The company reported no disagreements with EY during 2024–2025 or through June 12, 2026, and no reportable events except a previously disclosed material weakness in internal control over financial reporting that management later concluded had been remediated.

Key Details

• Dismissal and appointment effective June 12, 2026; PwC appointment is subject to standard client acceptance.
• EY’s reports for FY 2025 and FY 2024 were not qualified or modified; no disagreements per Item 304 of Regulation S‑K.
• The only reportable event previously disclosed was a material weakness related to inventory reconciliations (reported in the FY 2024 10‑K) that management reported as remediated in the FY 2025 10‑K.
• A letter from EY to the SEC dated June 15, 2026 is filed as Exhibit 16.1; the company did not consult with PwC on the matters described in Item 304 for the covered periods.

Why It Matters
An auditor change is a material governance event investors track because it affects who will audit and opine on the company’s financials going forward. This filing shows the change was administrative rather than adversarial: EY’s prior opinions were unqualified, there were no unresolved disagreements, and the only prior internal control issue has been reported as remediated. Investors should note that PwC will be responsible for the FY 2026 audit (subject to acceptance) and look for PwC’s audit opinion and any related disclosures in upcoming filings.